Abstract

Efficacy of Janus Kinase Inhibitors in the Treatment of Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis

Author(s): David Brooks*

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that can lead to joint damage and disability. Janus kinase (JAK) inhibitors have emerged as promising oral therapies for PsA, but their comparative efficacy remains unclear. This systematic review and network meta-analysis evaluates the efficacy and safety of JAK inhibitors, including tofacitinib and upadacitinib, against biologic therapies and conventional DMARDs. Our results demonstrate that JAK inhibitors have comparable efficacy to biologics in controlling disease activity and improving physical function, with a favorable safety profile. However, the review highlights the need for long-term safety data to guide their use in clinical practice.